Edarbyclor: payments to doctors
Payments that named Edarbyclor as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $202K
- Providers
- 6,020
- Transactions
- 13,307
- Average per transaction
- $15
The per-transaction average — $15 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 6,020 providers the average total is $34, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Arbor Pharmaceuticals, Inc. | $171,056 | 84.7% |
| Azurity Pharmaceuticals, Inc. | $30,705 | 15.2% |
| Takeda Pharmaceuticals U.S.A., Inc. | $137 | 0.1% |